LENZ Therapeutics (LENZ) Cash from Restructuring (2024)
LENZ Therapeutics' (LENZ) quarterly Cash from Restructuring came in at -$4.8 million in Q2 2024, down 199.13% on a QoQ basis from $4.8 million in Q1 2024.
LENZ Therapeutics (LENZ) Cash from Restructuring (2024) Analysis & Trends
LENZ Therapeutics (LENZ) has 1 years of Cash from Restructuring data on file, last reported at -$4.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -4.77 Mn |
| Mar 31, 2024 | 4.82 Mn |